TY - JOUR A1 - Hartl, Dominik A1 - de Luca, Valeria A1 - Kostikova, Anna A1 - Laramie, Jason A1 - Kennedy, Scott A1 - Ferrero, Enrico A1 - Siegel, Richard A1 - Fink, Martin A1 - Ahmed, Sohail A1 - Millholland, John A1 - Schuhmacher, Alexander A1 - Hinder, Markus A1 - Piali, Luca A1 - Roth, Adrian T1 - Translational precision medicine: an industry perspective JF - Journal of Translational Medicine N2 - In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective. UR - https://doi.org/10.1186/s12967-021-02910-6 KW - Translational medicine KW - Precision medicine KW - Drug development KW - Biomarkers KW - Multi-omics KW - Modeling KW - Artificial intelligence KW - Pharmaceutical industry KW - Digital biomarkers KW - Companion diagnostics Y1 - 2021 UR - https://doi.org/10.1186/s12967-021-02910-6 UR - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:573-39873 SN - 1479-5876 VL - 19 PB - BioMed Central CY - London ER -